asbestos lawyers - Worthington & Caron, PC

Over $2.5 billion

obtained for mesothelioma patients & families

In The News

A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function

Tazemetostat is an investigational drug that kills cancer cells by stopping a gene called EZH2 from working. EZH2 affects how two other genes, INI1 and SMARCA4 work in cells.

In early clinical development, tazemetostat has demonstrated clinical activity and a generally well-tolerated safety profile in both patients with hematological malignancies and genetically defined solid tumors.

Currently, tazemetostat is being used as a single-agent therapy in multiple clinical trials, including Phase 2 clinical trials in patients with mesothelioma.

Please click on this link to determine your eligibility and latest clinical trial locations.

Get Empowered

We put your medical and personal needs first and provide compassionate representation.

Speak with an Attorney